Constellation Pharmaceuticals (NASDAQ:CNST) Reaches New 1-Year High at $53.43

Constellation Pharmaceuticals Inc (NASDAQ:CNST) shares reached a new 52-week high during trading on Monday . The stock traded as high as $53.43 and last traded at $53.43, with a volume of 168310 shares. The stock had previously closed at $43.70.

CNST has been the subject of several research reports. Oppenheimer upped their target price on Constellation Pharmaceuticals from $18.00 to $40.00 in a report on Wednesday, November 6th. Royal Bank of Canada lifted their target price on Constellation Pharmaceuticals to $42.00 and gave the company a “positive” rating in a research note on Thursday, November 7th. Zacks Investment Research lowered shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. ValuEngine lowered shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Finally, HC Wainwright raised their target price on shares of Constellation Pharmaceuticals from $18.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Constellation Pharmaceuticals has a consensus rating of “Buy” and an average target price of $32.96.

The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -9.92 and a beta of 6.88. The firm’s 50 day simple moving average is $29.03 and its 200 day simple moving average is $13.86. The company has a debt-to-equity ratio of 0.81, a quick ratio of 5.19 and a current ratio of 5.19.

Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Wednesday, November 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. As a group, sell-side analysts forecast that Constellation Pharmaceuticals Inc will post -2.99 earnings per share for the current year.

In related news, major shareholder Group L. P. Column purchased 1,411,764 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were purchased at an average cost of $8.50 per share, with a total value of $11,999,994.00. Also, insider Adrian Senderowicz sold 27,232 shares of Constellation Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $30.91, for a total value of $841,741.12. In the last three months, insiders sold 317,971 shares of company stock valued at $10,976,079. 43.70% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in CNST. BlackRock Inc. raised its holdings in Constellation Pharmaceuticals by 13.0% in the 2nd quarter. BlackRock Inc. now owns 820,432 shares of the company’s stock valued at $10,074,000 after acquiring an additional 94,107 shares during the last quarter. P.A.W. Capital Corp acquired a new stake in shares of Constellation Pharmaceuticals during the 2nd quarter worth approximately $1,474,000. Vanguard Group Inc. lifted its holdings in Constellation Pharmaceuticals by 30.7% in the second quarter. Vanguard Group Inc. now owns 530,331 shares of the company’s stock valued at $6,513,000 after acquiring an additional 124,591 shares during the last quarter. Alps Advisors Inc. purchased a new position in Constellation Pharmaceuticals in the second quarter worth approximately $663,000. Finally, Acadian Asset Management LLC acquired a new stake in Constellation Pharmaceuticals during the second quarter worth $61,000. 60.63% of the stock is owned by institutional investors and hedge funds.

Constellation Pharmaceuticals Company Profile (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

See Also: Economic Reports

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.